https://scholars.lib.ntu.edu.tw/handle/123456789/630359
標題: | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice | 作者: | Hsuan, Chin-Feng Teng, Sean I F Hsu, Chih-Neng Liao, Daniel Chang, Allen Jiun-Wei Lee, Hsiao-Lin Hee, Siow-Wey YI-CHENG CHANG LEE-MING CHUANG |
關鍵字: | diabetic cardiomyopathy; emerging therapy; mechanism | 公開日期: | 22-二月-2023 | 出版社: | MDPI | 卷: | 11 | 期: | 3 | 來源出版物: | Biomedicines | 摘要: | Diabetic cardiomyopathy is characterized by abnormal myocardial structure or performance in the absence of coronary artery disease or significant valvular heart disease in patients with diabetes mellitus. The spectrum of diabetic cardiomyopathy ranges from subtle myocardial changes to myocardial fibrosis and diastolic function and finally to symptomatic heart failure. Except for sodium-glucose transport protein 2 inhibitors and possibly bariatric and metabolic surgery, there is currently no specific treatment for this distinct disease entity in patients with diabetes. The molecular mechanism of diabetic cardiomyopathy includes impaired nutrient-sensing signaling, dysregulated autophagy, impaired mitochondrial energetics, altered fuel utilization, oxidative stress and lipid peroxidation, advanced glycation end-products, inflammation, impaired calcium homeostasis, abnormal endothelial function and nitric oxide production, aberrant epidermal growth factor receptor signaling, the activation of the renin-angiotensin-aldosterone system and sympathetic hyperactivity, and extracellular matrix accumulation and fibrosis. Here, we summarize several important emerging treatments for diabetic cardiomyopathy targeting specific molecular mechanisms, with evidence from preclinical studies and clinical trials. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630359 | ISSN: | 2227-9059 | DOI: | 10.3390/biomedicines11030662 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。